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Factor H autoantibodies have been re-
ported in approximately 10% of patients
with atypical hemolytic uremic syndrome
(aHUS) and are associated with defi-
ciency of factor H–related proteins 1 and
3. In this study we examined the preva-
lence of factor H autoantibodies in the
Newcastle cohort of aHUS patients, deter-
mined whether the presence of such auto-
antibodies is always associated with defi-
ciency of factor H–related proteins 1 and
3, and examined whether such patients
have additional susceptibility factors
and/or mutations in the genes encoding
complement regulator/activators. We
screened 142 patients with aHUS and
found factor H autoantibodies in 13 indi-
viduals (age 1-11 years). The presence of
the autoantibodies was confirmed by
Western blotting. By using multiplex
ligation-dependent probe amplification we
measured complement factor H–related
(CFHR)1 and CFHR3 copy number. In
10 of the 13 patients there were 0 copies
of CFHR1, and in 3 patients there were 2.
In 3 of the patients with 0 copies of
CFHR1 there was 1 copy of CFHR3, and
these individuals exhibited a novel dele-
tion incorporating CFHR1 and CFHR4. In
5 patients mutations were identified: 1 in
CFH, 1 in CFI, 1 in CD46, and 2 in C3. The
latter observation emphasizes that mul-
tiple concurrent factors may be neces-
sary in individual patients for disease
manifestation. (Blood. 2010;115:379-387)
Introduction
It is now well established that atypical hemolytic uremic syndrome
(aHUS) is a disease of complement dysregulation.1 Mutations have
been found in the genes encoding both complement regulators
(factor H, factor I, and membrane cofactor protein) and comple-
ment activators (factor B and C3) in approximately 50% of
patients.2-6 In addition, factor H autoantibodies have been de-
scribed in a further approximately 10% of patients.7-9 These
antibodies have been shown to block the C-terminal recognition
domain of factor H,8 an area in which it is known that complement
factor H (CFH) mutations are associated with aHUS cluster.10 In
addition it has been shown that the majority of patients with
factor H autoantibodies have associated complete deficiency of
factor H–related proteins 1 and 39 secondary to a homozygous
deletion of the genes (complement factor H–related [CFHR]1 and
CFHR3) that encode these proteins. This deletion occurs secondary
to nonallelic homologous recombination (NAHR) in segmental
duplications in the regulators of complement activation gene
cluster at chromosome 1q32 and is known to be associated with an
increased risk of aHUS,11 especially in particular subgroups.12
NAHR is also known to predispose to the formation of a hybrid
complement gene associated with aHUS.13
Recent studies have shown that patients with aHUS may have
mutations in more than one complement regulator/activator, but
such mutations have not been described in association with
factor H autoantibodies. It is also well established that there are
additional susceptibility factors (single nucleotide polymorphisms
[SNPs] and haplotype blocks) in CFH and CD46 that increase the
risk of developing aHUS.14 In this study we have therefore
examined the prevalence of factor H autoantibodies in the New-
castle cohort of aHUS patients, determined whether the presence of
such autoantibodies is always associated with deficiency of factor H–
related proteins 1 and 3, and examined whether such patients have
additional susceptibility factors and/or mutations in the genes
encoding complement regulators/activators.
Methods
Subjects
Patients from the Newcastle cohort of aHUS (n 5 308) were included in
this study. Serum samples at the time of or shortly after presentation were
available from 142 aHUS patients, and of these paired DNA samples were
available for 128. Control paired serum and DNA samples were available
from 100 local blood donors. The study was approved by the Northern and
Yorkshire Multi-Center Research Ethics Committee and informed consent
obtained in accordance with the Declaration of Helsinki.
Factor H autoantibody assay
This assay was undertaken in 142 aHUS patients and 100 control subjects.
Flexible 96-well plates were coated with 5 mg/mL of purified factor H
(Merck Chemicals Ltd) or bovine serum albumin (BSA; Sigma) or molar
equivalents of factor H fragments (short consensus repeats [SCRs] 1-4,
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8-15, 19-20)15,16 or molar equivalents of a factor H–related protein 1
fragment (SCRs 4-5)16 in 0.1M carbonate buffer, pH 9.6, and incubated
overnight at 4°C. Plates were then washed thrice with phosphate-buffered
saline (PBS)/Tween 0.05%, followed by blocking in PBS/Tween 0.05%/
BSA 1% for 1 hour at room temperature. After blocking, a 1/50 dilution of
sera in PBS/Tween 0.05% was loaded in triplicate and incubated for 1 to
2 hours. Plates were washed thrice and then blocked as described previ-
ously. Goat anti-human IgG horse radish peroxidase (HRP, Stratech
Scientific) at 1/4000 was then added and incubated for 1 hour at room
temperature. Plates were then washed twice with PBS/Tween 0.05% and
twice with PBS. OPD solution was prepared according to the manufactur-
er’s instructions (Merck Chemicals Ltd) and added to each well for exactly
15 minutes before the reaction was stopped by the use of 10% sulfuric acid.
Plates were then analyzed with the use of a MULTISKAN Ascent plate
reader (Thermo-Scientific). Triplicate data were analyzed and mean BSA
readings subtracted from mean factor H readings to control for anti-BSA/
false-positive results.
SDS-PAGE and Western blotting
Detection of factor H autoantibody. Purified complement factor H
(Comptech) was diluted in solubilizing buffer and loaded onto a 10%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
preparative gel. After transfer to nitrocellulose and blocking as described
previously, the nitrocellulose was cut into 0.5- to 1-cm wide strips. These
strips were then incubated with individual sera samples (1/100 in 5% dried
milk/PBS) for 1 to 2 hours at room temperature. After washing as described
previously, bound autoantibody was detected by the use of goat anti-human
IgG-HRP incubated for 1 to 2 hours at room temperature. Blots were then
washed twice with PBS/0.1% Tween 20 and with PBS only. All blots were
developed by the use of an enhanced chemiluminescence (ECL) substrate
(Pierce) according to the manufacturer’s specifications.
Detection of factor H and factor H–related protein 1. Sera was
diluted 1/100 in solubilizing buffer and electrophoresed on 10% SDS-
PAGE gels, blotted onto nitrocellulose, and blocked with 5% dried
milk/PBS. Sections of the blots were incubated overnight at 4°C with either
polyclonal goat anti-human factor H (1/10 000 or 1/50 000 as appropriate;
Comptech) or C18/3 (1/2000; Santa Cruz Biotechnology Inc) in 5% dried
milk/PBS. Blots were washed 3 times in PBS/0.1% Tween 20 and
subsequently incubated with donkey anti-goat-HRP or goat anti-mouse-
HRP (1/3000 in 5% dried milk/PBS), as appropriate. After 1 to 2 hours at
room temperature, blots were washed twice with PBS/0.1% Tween 20 and
with PBS only.
Detection of factor H–related protein 3. This step was similar to
factor H and factor H–related protein 1, but sera also was incubated with
anti-HSA beads (Sartorious) for 30 minutes before analysis to remove
albumin. After this step, a 1/500 dilution of a rabbit polyclonal anti–factor H–
related protein 3 (a generous gift from Professor P. Zipfel, Leibniz Institute
for Natural Product Research and Infection Biology, Jena, Germany) with a
goat anti–rabbit–HRP as secondary was used to probe the nitrocellulose.
Measurement of CFHR1, CFHR3, and CFHR4 copy number
CFHR1 and CFHR3 copy number was measured in 196 aHUS patients
(including the 128 patients with paired serum and DNA samples) and
505 control subjects. The normal control subjects comprised 405 DNA
samples obtained from the Health Protection Agency Culture Collections17
and 100 DNA samples obtained from the aforementioned local blood
donors. The samples from the Health Protection Agency also were
originally obtained from a control population of randomly selected,
nonrelated United Kingdom white blood donors. CFHR1 and CFHR3 copy
number was measured by the use of multiplex ligation-dependent probe
amplification 18 with a kit from MRC Holland (SALSA MLPA kit P236-A1
ARMD). In this kit there are 5 probes for CFHR1 and 6 for CFHR3. Details
of these probes are given in Table 1.
CFHR4 copy number was measured by the use of a multiplex
polymerase chain reaction (PCR) assay designed to amplify CFHR4 exon 2
and intron 1. CFHR1 copy number was measured by the use of the same
multiplex assay designed to amplify CFHR1 introns 3 and 5. This acted as
an internal control for the CFHR4 assay. PCRs were carried out in 25-mL
volumes with the use of 150 ng of DNA and contained 0.5mM each dNTP,
6.7mM MgCl2, 12.5pM of each primer, 1 U of a hot-start Taq polymerase
(Immolase, Bioline) in a buffer of 16mM (NH4)2SO4, 67mM Tris-HCI, and
0.01% Tween-20. PCR cycling conditions were such that amplification
remained in the linear phase of the reaction (95°C for 10 minutes, with
20 cycles of 94°C for 45 seconds, 60°C for 45 seconds, 72°C for 1 minute,
and a final extension of 10 minutes at 72°C). Primers that amplify KCNT2
exon 9 and KCNT2 exon 17 were included in the assay as controls for
Table 2. Primer sequences for the CFHR1 and CFHR4 QF-PCR dosage analysis
Exon Forward (5*-3*) Reverse (5*-3*) bp
KCNT2, exon 17 TGAATCGATGATGTATCTGCAA AGTGGCCCTACCCTGTCTCT 98
CFHR1, intron 5 CAAAATAATCACAGATTATTGAACAACC CACACCCAGCCCTAAAGAGA 106
CFHR4, exon 2 CGCGTAGACCATACTTTCCA ACCCATCTTGTGTGCAGTGA 117
CFHR4, intron 1 TCTAAACACTCAGCTTCCCTCT TCTCACAAAATATGCTACTTCTGC 126
CFHR1, intron 3 ACGGAATCAAAAATGTCGAAATAG TCATCAGAGAGTTTCAGGTCCA 135
KCNT2, exon 9 GTAGAACCACAAGAGCAACAC ATAGGAAAGAAGCTGAATCTC 145
bp indicates base pair; CFHR1, complement factor H–related; and QF-PCR, quantitative fluorescence polymerase chain reaction.
Table 1. MLPA probes used to determine CFHR1 and CFHR3 copy number
Gene, exon Ligation site
Partial sequence
(20 nucleotides adjacent to ligation site)
CFHR3, exon 1 Intron 1 AGGTAAGTTA-AAAGAGATCT
CFHR3, exon 2 Intron 1 CATTTTCTTG-TGGAATTACA
CFHR3, exon 3 Intron 3 CGGACGACAG-TCTCAGACTT
CFHR3, exon 4 Intron 4 GGGTTATATG-AATTCCTACA
CFHR3, exon 6 Intron 5 TTCCCCAACA-TCACAGCAGA
CFHR3, exon 6 1003-1002 reverse TCCCTTCCCG-ACACACTGCT
CFHR1, exon 1 Intron 1 GGATAATTCA-ATTGAAATGG
CFHR1, exon 3 Intron 3 AGAGTTTCAG-GTCCATGTGT
CFHR1, exon5 Intron 5 AATCTGTGAT-TATTTTGTTA
CFHR1, exon 6 945-946 CCTGTTCTCA-AATAAAAGCTT
CFHR1, exon 6 1246-1247 TTTTCCAAGT-TTTAATATGG
CFHR1 indicates complement factor H–related; and MLPA, multiplex ligation-dependent probe amplification.
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normal dosage. One of each pair of primers was fluorescently labeled
(59FAM), and all primers are shown in Table 2. After PCR, amplification
products were analyzed by capillary electrophoresis (ABI, PerkinElmer).
Peak areas were obtained for each sample and dosage quotients calculated.
Complement assays
C3 and C4 levels were measured by rate nephelometry (Beckman Array
360). Factor H and factor I levels were measured by radioimmunodiffusion
(Binding Site). The normal ranges were C3 (0.68-1.38 g/L), C4 (0.18-0.60 g/
L), factor H (0.35-0.59 g/L), and factor I (38-58 mg/L).
Mutation screening and genotyping
In all patients found to have factor H autoantibodies mutation, screening of
CFH, CD46, CFI, CFB, and C3 was or had previously been undertaken by
the use of direct fluorescent sequencing as described.2-4,6,19 Genotyping of
the following SNPs was undertaken by the use of direct sequencing: CD46
-652A.G (rs2796267), CD46 -366A.G (rs2796268), CD46 c.4070T.C
(rs7144), CFH -331C.T (rs3753394), CFH c.2016A.G p.Gln672Gln
(rs3753396), and CFH c.2808G.T p.Glu936Asp (rs1065489).
Results
Factor H autoantibodies
In enzyme-linked immunosorbent assays (ELISAs), the mean
optical density plus 2SD in the control group before BSA
subtraction was 0.215. Eight control patients and 37 aHUS patients
had an OD reading greater than or close to this value (Figure 1A).
BSA subtraction was undertaken in all these samples. Subsequently
13 patients and 1 control patient had an OD greater than 0.2 (Figure
1B). This cutoff was used to identify the presence of a factor H
autoantibody. The specificity of the autoantibodies was confirmed
in all 13 patients and the 1 control subject by Western blotting
(Figure 2). By the use of a standard strip blot approach, patient sera
was exposed to factor H immobilized on nitrocellulose and any
factor H–specific human IgG detected. By the use of this approach,
autoantibody binding to factor H was demonstrated for all subjects
originally identified by ELISA. Signal intensity varied between
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Figure 1. Detection of factor H autoantibodies. Factor H autoantibodies in aHUS patients and control subjects were detected by the use of a sensitive ELISA as described in
“Factor H autoantibody assay.” (A) OD492 for 100 control subjects and 142 aHUS patients. (B) OD492 for 8 control subjects and 37 aHUS patients with an uncorrected OD
value greater than or close to 0.215 (the mean 1 2SD for the 100 control subjects) after background reactivity to BSA has been subtracted to exclude false-positive
interactions. The identity of the 13 factor H autoantibody–positive patients is shown.
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Figure 2. Analysis of antifactor H binding by Western blotting. Purified factor H was run out on 10% SDS-PAGE and transferred to nitrocellulose. Strips of nitrocellulose
were then incubated with sera collected from subjects and bound antibody detected as described in “Methods.” ECL Western blotting substrate was used to visualize bound
antibody. The same secondary reagent and exposure times were used throughout. Sera from known factor H autoantibody–positive and –negative subjects were used to allow
standardization across multiple experiments. The positive (1ve) and negative controls (2ve) are on adjacent strips on the same autorad film and are shown as representative
control signals (black box). The factor H autoantibody patients (1-13) and 2 normal subjects, A and B, are shown. These data are from a collection of sequential experiments.
Molecular weight markers are shown, and the data are representative of at least 3 independent experiments.
FACTOR H Abs IN aHUS: DELETIONS AND MUTATIONS 381BLOOD, 14 JANUARY 2010 z VOLUME 115, NUMBER 2
patients, but in general strong responses via ELISA were mirrored
in the western blot analysis.
Binding of autoantibodies to CFH and CFHR1 fragments
The site of binding of the autoantibodies was determined with the
use of factor H fragments SCRs 1 to 4, 8 to 15, 19 to 20, and a
factor H–related protein 1 fragment SCR 4 to 5 (Figure 3).
Antibodies from 1 patient (number 6, CFHR1 copy number 2)
bound only to factor H SCR 1 to 4, from 1 patient (number 12,
CFHR1 copy number 0) they bound only to factor H SCR 8 to 15,
and from 7 patients (numbers 2, 3, 4, 7, 8, 10, and 11) they bound to
both factor H SCR 19 to 20 and factor H–related protein 1 SCR 4 to
5 in a similar pattern. Of these 7 patients, 6 had 0 copies of CFHR1,
and 1 (number 7) had 2 copies of CFHR1. Three patients (numbers
1, 5, and 9) demonstrated binding to full-length factor H but not to
any of these fragments. The control subject with a positive factor H
autoantibody demonstrated binding to factor H SCR fragment 8 to
15 with an OD 490 of 1.18.
CFHR1, CFHR3, and CFHR4 copy number
Homozygous deletion of CFHR1 was significantly more fre-
quent in the aHUS patients than control subjects (aHUS 12.8%
vs control 3.0%). Likewise the allele frequency of CFHR1
deletion was significantly greater in aHUS patients than in
control subjects (aHUS 26.5% vs control 17.3%; Tables 3-4).
The CFHR1 deletion frequency in the aHUS patients is not
consistent with Hardy-Weinberg equilibrium (P 5 2.8 3 1024).
This finding is the result of an excess of homozygous CFHR1
deletion in the aHUS patients; the frequency of heterozygous
CFHR1 deletion was very similar in aHUS patients and control
subjects (aHUS 27.6% vs control 28.7%). In the 13 factor H
autoantibody–positive patients, 10 had 0 copies of CFHR1.
However, 3 patients (6, 7, and 9) had 2 copies of CFHR1, as did
the 1 control patient who had detectable factor H autoantibod-
ies. This patient’s status was confirmed at a protein level by
Western blotting (Figure 4). In the 128 aHUS patients with
paired serum and DNA samples, there were 6 patients who had
no copies of either CFHR1 or CFHR3 whose serum samples did
not show evidence of factor autoantibodies. In the 10 patients
who were positive for factor H autoantibodies and had 0 copies
of CFHR1, there were 3 (patients 3, 4, and 10) who had a single
copy of CFHR3 rather than none. This finding was confirmed by
Western blotting (Figure 4) with the use of factor H–related
protein 3 antisera (kindly provided by Professor Peter Zipfel). In
these 3 patients we demonstrated that this finding was caused by
the presence of a novel deletion (; 125 kb) in the regulators of
complement activation (RCA) cluster that incorporates CFHR1
and CFHR4, leaving CFHR3 intact (Figure 5).
Using quantitative PCR we showed that these 3 patients (3, 4, and
10) had 1 copy of CFHR4, whereas the remaining 10 all had
2 copies of CFHR4. Thus, in these 3 patients there was on 1 allele a
deletion of CFHR3/CFHR1 and on the other allele a CFHR1/
CFHR4 deletion. In 143 aHUS patients, copy number of both
CFHR3 and CFHR1 was measured. In 4 of these patients there was
evidence of a heterozygous CFHR1/CFHR4 deletion, including the
3 aforementioned patients who were found to have factor H
autoantibodies. A serum sample was not available for the other
patient. In all 4 patients there was evidence of a CFHR3/CFHR1
deletion on the other allele. Therefore, the allele frequency of the
CFHR1/CFHR4 deletion in aHUS patients is 1.4%. In 505 control
subjects there were 9 individuals with evidence of a heterozygous
CFHR1/CFHR4 deletion. In 2 of these there was evidence of a
CFHR3/CFHR1 deletion on the other allele. Therefore, the allele
frequency of the CFHR1/CFHR4 deletion is 0.9% in control
subjects. There was no significant difference between aHUS
Figure 3. Autoantibody reactivity with short factor H fragments.
Autoantibody binding to factor H fragments (corresponding to SCRs 1-4,
8-15, and 19-20) and a factor H–related protein 1 fragment (SCR 4-5) was
assessed by the use of ELISA in a similar manner to the original
autoantibody screen. Molar equivalent concentrations of the SCR frag-
ments were coated onto separate ELISA plates, and a BSA subtraction
was performed. Results are representative of 3 separate experiments.
Table 3. CFHR1 copy number in aHUS patients and control subjects
CFHR1 copy number aHUS (n 5 196) Controls (n 5 505)
0 25 15
1 54 145
2 115 342
3 2 3
aHUS indicates atypical hemolytic uremic syndrome; and CFHR1, complement
factor H–related 1.
x2 5 25.9; P 5 1.0 3 1025.
Table 4. CFHR1 allele frequency in aHUS patients and control
subjects
CFHR1 allele frequency aHUS patients (n 5 196) Controls (n 5 505)
Deleted 104 175
Present 288 835
aHUS indicates atypical hemolytic uremic syndrome; CFHR1, complement factor
H–related 1.
x2 5 15.0; P 5 1.1 3 1024.
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patients and control subjects in the allele frequency of the
CFHR1/CFHR4 deletion (x2 5 1.318, DF 5 1, P 5 .251), but
there was insufficient power for us to be certain. However, the
combination of a CFHR3/CFHR1 deletion on one allele and a
CFHR1/CFHR4 deletion on the other was significantly more
frequent in the aHUS patients (x2 5 7.004, DF 5 1, P 5 .008).
Clinical details of the patients with factor H autoantibodies
The clinical details of the 13 patients with factor H autoantibodies
are shown in Table 5. There were 6 male and 7 female patients, and
the median age at presentation was 8 years (range, 1-11 years). The
median length of follow-up was 6 years (range, 1-11 years). Seven
patients have regained renal function, 2 of these are on prophylactic
long-term plasma exchange, and 1 has had 3 relapses that were
successfully treated on each occasion with plasma exchange. Six
patients progressed to end-stage renal failure; of these, 3 have
received a renal allograft without recurrence in a follow-up period
ranging from 2 to 6 years. Levels of C3 were low in 3 patients
(numbers 1, 2, and 12) at presentation. One patient (number 5) had
a low factor H level, but mutation screening of CFH did not show
any abnormality. Mutation screening of CFH, CD46, CFI, CFB,
and C3 was undertaken in all patients with the use of direct
fluorescent sequencing as described previously (Table 6).2-4,6,19
One patient had a heterozygous sequence variant in CFH
(c.2850G.T, p.Gln950His), which has been described previously
in aHUS but has also been reported by one group in healthy
subjects.21 One patient who has been reported previously had a
sequence variant in CD46 (c.718T.C, Ser240Pro), which has been
shown to be functionally significant.4 A third patient had a
previously unreported sequence variant in exon 11 of CFI (Exon
11, c.1216C.T, p.Arg406Cys), which is predicted to be function-
ally significant. Two novel sequence variants were identified in C3
in 2 patients. One was in the 59UTR (c.-3_-2dup) and the other in
exon 15 (c.1898A.G;p.Lys633Arg). The genotyping results for
CD46 and CFH susceptibility factors are shown in Table 7. Ten of
the 13 patients were heterozygous for the at-risk G allele of CD46
-652A.G (rs2796267), and 2 were homozygous. Seven of the 13
patients were heterozygous for the at-risk G allele of CD46
-366A.G (rs2796268), and 4 were homozygous. Six of the
13 patients were heterozygous for the at-risk C allele of CD46
c.4070T.C (rs7144), and 4 were homozygous. From these results
we inferred that 8 patients (numbers 1, 3, 4, 5, 6, 7, 11, and 12)
were heterozygous for the at-risk CD46 haplotype CD46GGAAC, and
2 (numbers 2 and 10) were homozygous. Six patients were
heterozygous for the at risk T allele of CFH -331C.T (rs3753394),
and 2 were homozygous. One patient was homozygous for the
at-risk G allele of CFH c.2016A.G;p.Gln672Gln (rs3753396),
and 1 patient was homozygous for the at-risk allele of CFH
c.2808G . T;p.Glu936Asp (rs1065489). From these results we
inferred that 1 patient (number 6) was homozygous for the at-risk
CFHTGTGGT (H3) haplotype.
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Figure 4. Analysis of factor H, factor H–related protein 3, and factor H–related protein 1 in patients with factor H autoantibodies. Sera from subjects were run out on
10% SDS-PAGE and transferred to nitrocellulose. Factor H, factor H–related protein 3, and factor H–related protein 1 were then detected by staining as described in the
Methods section. ECL Western blotting substrate was used to visualize bound antibody. Sera was available from all 13 patients (samples 1-13) for analysis of factor H and
factor H–related protein 1, but only from 9 patients for factor H–related protein 3. These 9 samples plus control samples were run on parallel gels. A, B, and C are normal
controls known to have 2 copies of CFHR1 and CFHR3. Data from the remaining 3 samples are shown on the right. Purified factor H (equivalent to 0.5 mg/mL) was used as a
positive control (1) in the smaller antifactor H blot. Black vertical lines indicate a repositioned gel lane, and black boxes illustrate the individual blots used. This figure is
representative of several independent experiments.
Figure 5. A novel deletion including CFHR1 and CFHR4. Position of the genes encoding factor H and the factor H–related proteins in a centromeric segment of the RCA
cluster at 1q32. Regions of high sequence identity (originally determined by Male et al20) are indicated by the same letter and color. Exons are indicated as vertical lines. The
shaded box shows the presence of a novel ; 125-kb deletion, which includes CFHR1 and CFHR4. This deletion occurs within the duplicons C/C9 as a result of nonallelic
homologous recombination.
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Discussion
In this study we have found that 9.2% (13/142) of the Newcastle
cohort of aHUS patients had factor H autoantibodies at the time of
or shortly after presentation. This finding corresponds well with
previous reports. Dragon-Durey et al7 screened serum samples
from 48 children who presented with aHUS and found factor H
autoantibodies in 3 (6.3%). Jo´zsi et al8 screened plasma samples
from 60 patients and found autoantibodies in 5 (8.3%). We have
previously shown that deletion of the genes encoding factor H–
related proteins 1 and 3 is associated with aHUS.11 In particular it
has been shown that homozygous deletion of CFHR1 and CFHR3
is more frequent in aHUS than in control patients. It has recently
been shown that the presence of factor H autoantibodies is strongly
associated with complete deficiency of factor H–related proteins 1
and 3.9 Jo´zsi et al9 showed that in an extended cohort of 147 aHUS
patients, 16 (including those described in the previous study by
Jo´zsi et al8) had factor H autoantibodies. Of these 14 had
complete absence of factor H–related proteins 1 and 3 on
Western blotting, and 2 had low levels. In their cohort of
147 aHUS patients, there were 22 patients in total with complete
absence of factor H–related proteins 1 and 3. Thus, 14 (64%) of
22 patients with complete deficiency of factor H–related pro-
teins 1 had factor H autoantibodies.
This finding agrees well with our cohort, in which 10 (63%) of
16 patients with 0 copies of CFHR1 had factor H autoantibodies. In
Jo´zsi et al’s cohort,8 14 (88%) of 16 patients with factor H
autoantibodies had complete deficiency of both factor H–related
proteins 1 and 3. Again this finding agrees well with our cohort, in
which 10 (77%) of 13 patients with factor H autoantibodies had
0 copies of CFHR1. However, in contrast to Jo´zsi et al’s patients
with factor H autoantibodies, we found that 3 patients had 2 copies
of both CFHR1 and CFHR3 with no evidence of a deficiency of
Table 5. Clinical details of the aHUS patients with factor H autoantibodies
Patient
ID
Age at
presentation,
y Sex Clinical outcome
Length
of follow-up,
y Transplanted C3, g/L C4, g/L
Factor H,
g/L
Factor I,
mg/L
1 5 M Recovered renal function.
2 relapses. On PE
23/week
2 No 0.61 0.1 0.37 39
2 11 M Recovered renal function 5 No 0.57 0.15 0.44 70
3 8 F ESRF 9 No 0.86 0.25 0.49 58
4 4 F ESRF 1 No 0.89 0.3 0.52 41
5 10 F ESRF 5 Yes, 3 y
no recurrence
0.92 0.2 0.29 n/a
6 8 M ESRF 6 No 1.08 0.36 0.5 74
7 6 M ESRF 7 Yes, 2 years
no recurrence
0.77 0.28 0.56 77
8 1 M Recovered renal function 4 No 1.59 0.38 0.67 75
9 9 F Recovered renal function 11 No n/a n/a 0.63 n/a
10 5 M Recovered renal function;
multiple relapses; PE
13/2 weeks
3 No 1.06 0.13 0.45 68
11 4 F Recovered renal function;
3 relapses treated with
PE
6 No 0.85 0.24 n/a n/a
12 10 F ESRF 8 Yes, 6 y
no recurrence
0.51 0.23 0.57 62
13 9 F Recovered renal function 8 No n/a n/a n/a n/a
aHUS indicates atypical hemolytic uremic syndrome; ESRF, end-stage renal failure; F, female; M, male; n/a, not available; and PE, plasma exchange.
Table 6. Mutation screening of CFH, CD46, CFI, CFB, C3, and measurement of CFHR1, CFHR3, and CFHR4 copy number
Patient
ID CFH CD46 CFI CFB C3
Copy number
CFHR1 CFHR3 CFHR4
1 nmd nmd nmd nmd nmd 0 0 2
2 nmd nmd nmd nmd c.-3_-2dup 0 0 2
3 nmd nmd nmd nmd nmd 0 1 1
4 nmd nmd Exon 11, c.1216C.T;p.Arg406Cys nmd nmd 0 1 1
5 nmd nmd nmd nmd c.1898A.G;p.Lys633Arg 0 0 2
6 nmd nmd nmd nmd nmd 2 2 2
7 nmd nmd nmd nmd nmd 2 2 2
8 nmd nmd nmd nmd nmd 0 0 2
9 nmd c.718T.C;p. Ser240Pro nmd nmd nmd 2 2 2
10 nmd nmd nmd nmd nmd 0 1 1
11 nmd nmd nmd nmd nmd 0 0 2
12 c.2850G.T; p.Gln950His nmd nmd nmd nmd 0 0 2
13 nmd nmd nmd nmd nmd 0 0 2
CFHR indicates complement factor H–related; and nmd, no mutation detected.
384 MOORE et al BLOOD, 14 JANUARY 2010 z VOLUME 115, NUMBER 2
factor H–related protein 1 on Western blotting (Figure 4). Two of
these patients had the highest autoantibody titers of the whole
group. Thus, our data would suggest that a significant autoantibody
response to factor H can be mounted in the presence of normal
expression of factor H–related proteins 1 and 3.
A novel observation in our study is that in 3 patients the
complete deficiency of factor H–related protein 1 is caused by a
deletion encompassing CFHR3 and CFHR1 on one allele and
CFHR1 and CFHR4 on the other. This novel deletion (CFHR1/
CFHR4), like the previously described CFHR3/1 deletion, has
probably occurred as a result of nonallelic homologous recombina-
tion through segmental duplications in this region of the RCA
cluster (as shown in Figure 5). The allele frequency of this deletion
in both our control patients and aHUS patients is low (0.9% vs
1.4%). With the power available to us, there was no significant
difference between the 2 groups. However, the presence of this
deletion on one allele and the CFHR3/1 deletion on the other
resulting in complete deficiency of factor H–related protein 1 was
significantly more common in the aHUS cohort. This finding
suggests that it is probably complete deficiency of factor H–related
protein 1 that is the significant factor associated with the production
of factor H autoantibodies in aHUS. How complete deficiency of
factor H–related protein 1 might predispose one to the development
of factor H autoantibodies in aHUS is not known. It is possible that
it results in a failure of central and/or peripheral tolerance.
Are factor H autoantibodies pathogenic in aHUS? It is well
established that CFH mutations in aHUS cluster in the C-terminal
SCRs and that these mutations are associated with impaired control
of complement activation at cell surfaces.22 Moreover, a transgenic
murine model in which the mouse factor H lacks the 5 C terminal
SCRs (FHD16-20) spontaneously develops aHUS.23 Jo´zsi et al8
used recombinant fragments of factor H to map the binding site of
factor H autoantibodies in 5 patients. They showed in all 5 that the
binding site was in the C-terminal SCRs. In our study we have used
a similar approach. In agreement with Jo´zsi et al,8 we found that
autoantibodies from 7 patients showed binding to a fragment
comprising SCRs 19 to 20. Thus, most factor H autoantibodies in
aHUS bind to and impair the activity of the C-terminal SCRs of
factor H. This is the same region in which functionally significant
mutations cluster. Moreover, it has been shown that factor H
autoantibodies impair the binding of factor H to C3b and are
associated with enhanced hemolysis of sheep erythrocytes in
patient plasma.8 In addition we have shown that the autoantibodies
from the 7 patients with binding to the factor H fragment SCRs 19
to 20 cross-react with the homologous factor H–related 1 protein
fragment SCRs 4 to 5.
Our study is the first to show that in addition to the presence of
factor H autoantibodies some patients have mutations in comple-
ment genes. In 1 patient we found a CFH mutation, in another a
CFI mutation, in another we had already found and reported a
functionally significant CD46 mutation,4 and in 2 other patients we
found novel C3 variants. Although the functional significance of
some of these sequence variants remains to be established, this
finding strengthens the suggestion that multiple concurrent suscep-
tibility factors are necessary in some aHUS patients for the disease
to become manifest.14
In patients with CFH, CFI, CD46, CFB, and C3 mutations it is
now well recognized that additional variants (SNPs and haplotype
blocks) in CFH and CD46 act as susceptibility factors for the
development of the disease.24 One particular CFH haplotype,
CFHTGTGGT (also known as the CFH-H3), is associated with an
increased risk of aHUS. This haplotype is defined by the following
SNPs -331C.T (rs3753394), c.184G.A Val62Ile (rs800292),
c.1204T.C p.Tyr402His (rs1061170), c.2016A.G p.Gln672Gln
(rs3753396), IVS15-543G.A intron 15 (rs1410996), and
c.2808G.T p.Glu936Asp (rs1065489), where the at-risk alleles
are in bold. The at-risk haplotype can be tagged by genotyping
rs3753394, rs3753396, and rs1065489; we have done this in all
13 patients. This haplotype was present in only 1 patient (number
6) in homozygosity. Of interest, this patient had 2 copies of both
CFHR3 and CFHR1. It has recently been established that the
CFHR3/1 deletion is associated with particular CFH haplotypes in
patients with age-related macular degeneration and control sub-
jects.25-27 In the study undertaken by Spencer et al,27 all deletion
homozygotes were homozygous for alleles GCGAAG at rs529825,
rs2019724, rs1831281, rs6677604, rs3753396, and rs1065489. In
our study all the factor H autoantibody–positive patients, who were
either homozygous for the CFHR3/1 deletion or had the CFHR3/1
deletion on one allele and the CFHR1/4 deletion on the other allele,
were homozygous for alleles “AG” at rs3753396 and rs1065489.
Interestingly, 2 patients (numbers 7 and 9) who had 2 copies of
CFHR1 and CFHR3 were also homozygous for alleles “AG” at
rs3753396 and rs1065489. This finding raises the possibility that
this particular CFH haplotype has a role in the pathogenesis of
factor H autoantibodies.
As with CFH there is a particular CD46 haplotype, CD46GGAAC,
associated with an increased risk of aHUS. This haplotype is
defined by the following SNPs -652A.G (rs2796267), -366A.G
(rs2796268), IVS9-78G.A (rs1962149), IVS121638G.A
(rs859705), and c.4070T.C (rs7144). The at-risk haplotype can be
tagged by genotyping rs2796267, rs2796268, and rs7144; we have
again undertaken this in all 13 factor H autoantibody–positive
Table 7. CD46 and CFH susceptibility factors
Patient
ID
CD46 2652A>G
(rs2796267)
CD46 2366A>G
(rs2796268)
CD46 c.4070T>C
(rs7144)
CFH 2331C>T
(rs3753394)
CFH c.2016A>G Gln672Gln
(rs3753396)
CFH c.2808G>T Glu936Asp
(rs1065489)
1 AG GG CC CT AA GG
2 GG GG CC CC AA GG
3 AG AG TC CC AA GG
4 AG AG TC CC AA GG
5 AG AG TC CC AA GG
6 AG AG TC TT GG TT
7 AG AG TC CT AA GG
8 AG AA TT CC AA GG
9 AG AG TT TT AA GG
10 GG GG CC CT AA GG
11 AG GG CC CT AA GG
12 AG AG TC CT AA GG
13 AA AA TT CT AA GG
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patients. We inferred that 8 (numbers 1, 3, 4, 5, 6, 7, 11, and 12)
were heterozygous for the at-risk CD46 haplotype, CD46GGAAC,
and 2 (numbers 2 and 10) were homozygous. This finding suggests
that CD46 may be acting as an additional susceptibility factor for
the development of aHUS in patients with factor H autoantibodies.
The clinical features of the 13 patients with factor H autoantibod-
ies that we describe here are similar to those previously reported.
All were children with an age at presentation ranging from 1 to
11 years. Of the 3 patients described by Dragon-Durey et al,7 only
1 developed end-stage renal failure. Of our 13 patients, 6 developed
end-stage renal failure, and 7 have maintained renal function to
date. Three of the patients who developed end-stage renal failure
have undergone transplantation without recurrence of the disease,
with a follow-up period ranging from 2 to 6 years. A recent report
documented the pretransplant administration of the anti-CD20
monoclonal antibody rituximab followed by intensive plasma
exchange postoperatively in a 10-year-old girl with factor H
autoantibodies.28 Before the administration of rituximab, the pa-
tient had been treated with prednisolone, azathioprine, and plasma
exchange in an attempt to decrease the autoantibody titer. However,
this was not achieved until after the administration of rituximab.
Subsequently there was no recurrence of the disease after trans-
plant, with a follow-up period of 2 years. We do not have serum
samples available from the immediate pretransplant period from
patients 5, 7, and 12 to determine autoantibody titer at that time, but
we have analyzed a recent convalescent sample from patient 12.
This sample was negative for factor H autoantibodies. This finding
suggests that the titer of factor H autoantibodies may spontane-
ously decline with time. A pragmatic approach to the transplant
management of patients with factor H autoantibodies would be to
regularly monitor antibody levels and administer rituximab to those
with persistently elevated titers.
In summary we have confirmed that factor H autoantibodies are
found in approximately 9% of patients with aHUS. While most
have complete deficiency of factor H–related protein 1, we have
shown that this is not a prerequisite. Moreover, we have shown that
deficiency of factor H–related protein 1 can arise from a novel
CFHR1/4 deletion and that mutations of CFH, CD46, CFI, and C3
are present in some patients. The latter observation provides further
evidence that multiple “hits” are necessary in some patients before
aHUS presents clinically.
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